Recommendation of the President – Lynparza (olaparib)

On 22 July 2024, the President of the Agency for Health Technology Assessment and Tariff System issued  recommendation No. 72/2024 on the evaluation of the drug Lynparza (olaparib) in the drug programme ‘Treatment of patients with prostate cancer (ICD-10: C61)’

Publication in Public Information Bulletin (BIP) >>